{"url_path":"/sec/lrmr/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-224087-index.html","accession_number":"0001193125-26-224087","cik":"0001374690","ticker":"LRMR","issuer_name":"Larimar Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1374690/0001193125-26-224087-index.html","primary_entity_key":"0001374690","primary_entity_name":"Larimar Therapeutics, Inc."},"word_count":332,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nThe exhibits filed as part of this Quarterly Report are set forth on the Exhibit Index, which is incorporated herein by reference.\n\nEXHIBIT INDEX\n\n \n\nExhibit No.\n\n \n\nDescription\n\n \n\n \n\n \n\n3.1\n\n \n\n[Certificate of Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-36510) filed on January 22, 2026).](https://www.sec.gov/Archives/edgar/data/1374690/000119312526018664/d27699dex31.htm)\n\n \n\n \n\n \n\n10.1\n\n \n\n[Exchange Agreement, dated January 21, 2026, by and between Larimar Therapeutics, Inc. and the Stockholder named therein (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 22, 2026).](https://www.sec.gov/Archives/edgar/data/1374690/000119312526018664/d27699dex101.htm)\n\n \n\n \n\n \n\n31.1*\n\n \n\n[Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](lrmr-ex31_1.htm)\n\n \n\n \n\n \n\n31.2*\n\n \n\n[Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](lrmr-ex31_2.htm)\n\n \n\n \n\n \n\n32.1**\n\n \n\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](lrmr-ex32_1.htm)\n\n \n\n \n\n \n\n101.INS*\n\n \n\nInline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tag re embedded within the Inline XBRL document\n\n \n\n \n\n \n\n101.SCH*\n\n \n\nInline XBRL Taxonomy Extension Schema Document.\n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)\n\n \n\n* Filed herewith.\n\n** Furnished herewith.\n\n32\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nLARIMAR THERAPEUTICS, INC.\n\n \n\n \n\n \n\nDate: May 14, 2026\n\n \n\nBy:\n\n \n\n/s/ Carole S. Ben-Maimon, M.D.\n\n \n\n \n\n \n\n \n\nCarole S. Ben-Maimon, M.D.\n\n \n\n \n\n \n\n \n\nPresident and Chief Executive Officer\n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: May 14, 2026\n\n \n\n \n\nBy:\n\n \n\n/s/ Michael Celano\n\n \n\n \n\n \n\n \n\nMichael Celano\n\n \n\n \n\n \n\n \n\nChief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n \n\n33"}